The emergence of drugs like copyright and Semaglutide signifies a remarkable shift in how we treat type 2 diabetes. These groundbreaking therapies belong to a class known as GLP-1 action agonists, which replicate the effects of a natural hormone that manages sugar levels and hunger. Initially, de